Form 4 for TBPH Theravance Biopharma, Inc.
Accepted 2026-04-03 18:10:24 ET · period of report 2026-04-01 · accession 0001302443-26-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-03 18:10 | 2026-04-01 | TBPH | Winningham Rick E | CEO, Dir | A - Grant | $0.00 | +75.0K | 1.65M | +5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-04-01 | A | A | 75,000 | $0.00 | 1,651,094 | D | — | — |